Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Xbiotech Inc (XBIT)

Xbiotech Inc (XBIT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 94,497
  • Shares Outstanding, K 30,483
  • Annual Sales, $ 0 K
  • Annual Income, $ -24,560 K
  • EBIT $ -42 M
  • EBITDA $ -41 M
  • 60-Month Beta 1.45
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.54

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 66.61%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.05 +1.64%
on 02/07/25
4.48 -30.80%
on 01/08/25
-1.16 (-27.23%)
since 01/07/25
3-Month
3.05 +1.64%
on 02/07/25
7.74 -59.95%
on 11/11/24
-4.26 (-57.88%)
since 11/07/24
52-Week
3.05 +1.64%
on 02/07/25
9.96 -68.88%
on 04/10/24
-2.37 (-43.33%)
since 02/07/24

Most Recent Stories

More News
XBiotech Pauses Rheumatology program

XBIT : 3.10 (-5.49%)
XBiotech: Q3 Earnings Snapshot

XBiotech: Q3 Earnings Snapshot

XBIT : 3.10 (-5.49%)
Junior Biotech Utilizes AI To Shorten Drug Discovery Timelines, Ultimately Saving Lives

The urgent need for innovative technologies to accelerate the development of life-saving %Cancer therapies has never been more critical. With millions of lives and billions of dollars at stake, the potential...

MRK : 87.28 (-0.87%)
NVS : 106.26 (-0.67%)
KTRA : 7.5390 (-6.31%)
RKV.VN : 0.200 (+5.26%)
RHHBY : 39.7700 (+0.40%)
XBIT : 3.10 (-5.49%)
BMRN : 63.93 (-0.64%)
AZN : 71.99 (-0.51%)
XBiotech: Q2 Earnings Snapshot

XBiotech: Q2 Earnings Snapshot

XBIT : 3.10 (-5.49%)
XBiotech: Q1 Earnings Snapshot

XBiotech: Q1 Earnings Snapshot

XBIT : 3.10 (-5.49%)
XBiotech Announces Successful Completion of Phase I portion of Pancreatic Cancer Study

Novel Natrunix Treatment Shows Promise in Combination Chemotherapy for Treatment of Pancreatic Cancer...

XBIT : 3.10 (-5.49%)
XBiotech Inks Clinical Manufacturing Deal

XBiotech Manufacturing Antibody Drug for Janssen Research & Development, LLC (Janssen), One of the Janssen Pharmaceutical Companies of Johnson & Johnson...

XBIT : 3.10 (-5.49%)
XBiotech Announces First Patient Enrolled in Phase I Clinical Trial for Novel Arthritis Therapy Natrunix-SQ

Natrunix-SQ, A True Human Antibody Therapy Discovered and Manufactured at XBiotech, Is Aimed as a Breakthrough Treatment for Arthritic Disease...

XBIT : 3.10 (-5.49%)
XBiotech to Launch Novel Candidate Therapy for Stroke

Company Commencing Phase I/II Study to Test Safety and Efficacy of its New Drug Candidate to Reduce Brain Injury After Stroke...

XBIT : 3.10 (-5.49%)
Dr. Benjamin Musher to Chair Phase 1-2 Study Evaluating XBiotech’s Natrunix™ Anti-Cancer Therapy in Pancreatic Cancer

AUSTIN, Texas, Sept. 08, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) today announced that Benjamin Musher M.D., will chair XBiotech’s clinical program for pancreatic cancer....

XBIT : 3.10 (-5.49%)

Business Summary

XBiotech Inc. is a biopharmaceutical company. The Company is engaged in discovering and developing True Human(TM) monoclonal antibodies for treating diseases. XBiotech Inc. is based in AUSTIN, United States.

See More

Key Turning Points

3rd Resistance Point 3.55
2nd Resistance Point 3.44
1st Resistance Point 3.27
Last Price 3.10
1st Support Level 2.99
2nd Support Level 2.88
3rd Support Level 2.71

See More

52-Week High 9.96
Fibonacci 61.8% 7.32
Fibonacci 50% 6.51
Fibonacci 38.2% 5.69
Last Price 3.10
52-Week Low 3.05

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar